You are here: Industry Insights > Neurimmune

News List

Neurimmune and Ono Pharmaceutical extend drug discovery partnership pharmaceutical-business-review
January 18, 2022
Neurimmune and Ono Pharmaceutical have announced the expansion of a drug discovery partnership agreement to develop antibody drugs for neurodegenerative diseases.
Neurimmune, Ono Expand Neurodegenerative Discovery Collaboration contractpharma
January 17, 2022
Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to create antibody drugs against new therapeutic targets in the field of neurodegenerative diseases using Neurimmune's...
AstraZeneca’s Alexion and Neurimmune sign antibody development deal Pharmaceutical-Technology
January 11, 2022
AstraZeneca’s Rare Disease group Alexion and Neurimmune have signed an exclusive worldwide partnership and licence agreement to develop NI006, a human monoclonal antibody.
Neurimmune and Ethris to develop mRNA antibody for Covid-19 pharmaceutical-technology
April 02, 2020
Swiss biopharmaceutical firm Neurimmune has partnered with German biotechnology company Ethris to develop mRNA-based, neutralising antibodies for a Covid-19 therapeutic formulated for inhalation.
Regenxbio, Neurimmune to Develop Antibodies for Neurodegenerative Disease Treatment contractpharma
July 26, 2019
Potential to deliver sustained levels of therapeutic human antibodies to the brain with AAV vectors.
Neurimmune Appoints John Dellapa as General Counsel b3cnewswire
March 05, 2019
Neurimmune today announced the appointment of John Dellapa as General Counsel.
NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke b3cnewswire
March 05, 2019
NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke...
Neurimmune’s anti-SOD1 antibody shows promise in ALS mouse studies fiercebiotech
January 02, 2019
Mutations in the gene SOD1 can cause the enzyme it encodes to fold in ways that are harmful to neurons—an abnormality that's responsible for about ....
Neurimmune achieves milestone with Ono Pharmaceutical biospectrumasia
September 29, 2018
Under the terms of the collaboration agreement Neurimmune conducts research to generate and validate human-derived monoclonal antibodies...
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab b3cnewswire
May 08, 2018
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab...

Previous page 1 2 Next page